In Depth 19 Jan 2024
Re-coding the brain: Is CRISPR capable of curing neurodegenerative diseases?
Check out our latest article as we explore some of the latest research around using CRISPR technology to treat neurodegenerative diseases.
Alzheimer’s
- Latest Posts
Podcast 12 Jan 2024
Could natural killer cells transform Alzheimer’s treatment?
Join Dr. Paul Song, CEO of NKGen Biotech, in a podcast exploring the revolutionary use of NK cells for Alzheimer’s treatment.
Best in Biotech 20 Dec 2023
Wrapping up 2023: A recap of top biotech moments of this year
2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023.
Podcast 15 Dec 2023
Vaxxinity making vaccines to change the world
Discover how Vaxxinity’s vaccine approach aims to democratize global health, potentially reshaping access to innovative treatments worldwide.
In Depth 30 Nov 2023
Could an Alzheimer’s vaccine make treatment more affordable?
Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […]
In Depth 9 Nov 2023
Blood tests for Alzheimer’s: a hit or a miss?
Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]
ADVERTISEMENT
ADVERTISEMENT
In Depth 26 Oct 2023
Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials
Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]
News and Trends 28 Jul 2023
Could a natural sweetener from hydrangeas treat Alzheimer’s disease?
Amyloid β (Aβ) aggregation is primarily responsible for the development of Alzheimer’s disease (AD). In a new mouse model study, South Korean researchers investigated the effect of phyllodulcin — a natural sweetener found in the hydrangea plant — in inhibiting Aβ accumulation. The results suggest that phyllodulcin effectively inhibits Aβ accumulation and decomposes the pre-aggregated […]
News and Trends 17 Jul 2023
Hope for Alzheimer’s patients after Lilly drug results
Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]
News and Trends 13 Jul 2023
Partnership to progress neurodegenerative disorder treatments
IRBM, Rainwater Charitable Foundation (RCF, Fort Worth, Texas), a private family foundation, and Weill Cornell Medicine (based in New York) are starting a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and […]
News and Trends 7 Jul 2023
FDA approves Alzheimer’s treatment
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]
News and Trends 23 Jun 2023
SandboxAQ launches new division to boost drug development
After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […]
ADVERTISEMENT
